NEW YORK (Reuters Health) – The proton pump inhibitor dexlansoprazole modified release (MR) relieves nocturnal heartburn in patients with gastroesophageal reflux disease (GERD), study findings show. As a…
NEW YORK (Reuters Health) – Nephron-sparing surgery is linked to better survival than radical nephrectomy for renal cell carcinoma, even among patients over age 80, study findings show.…
NEW YORK (Reuters Health) – After a first myocardial infarction, treatment with a calcium-channel blocker (CCB) does not appear to diminish the efficacy of clopidogrel, according to results…
NEW YORK (Reuters Health) – The use of artificial colloids for intravascular volume expansion is associated with greater risk of acute kidney injury and impaired coagulation than is…
NEW YORK (Reuters Health) – Children diagnosed with ulcerative colitis have a good chance of attaining remission after 1 year of treatment with azathioprine or 6-mercaptopurine, according to…
NEW YORK (Reuters Health) – An updated guideline from the American Academy of Neurology recommends plasmapheresis for severe relapses in multiple sclerosis and other inflammatory demyelinating neurologic disorders.…
NEW YORK (Reuters Health) – Depending on the particular regimen, insulin analogs can help 35% to 64% of patients with type 2 diabetes achieve the recommended hemoglobin A1C…
NEW YORK (Reuters Health) – In the emergency department, successful intubation on the first try is equally likely using either succinylcholine at a median dose of 1.65 mg/kg…
NEW YORK (Reuters Health) – In a small study of pregnant women with type 1 diabetes, use of a closed-loop insulin delivery system (also known as the artificial…
NEW YORK (Reuters Health) – Patients with ST-elevation myocardial infarction (STEMI) who present 12 to 24 hours after onset of symptoms should be considered for reperfusion by primary…
NEW YORK (Reuters Health) – A dexamethasone intravitreal implant is more likely to reduce inflammation and improve vision than a sham treatment in patients with noninfectious uveitis, investigators…
NEW YORK (Reuters Health) – A new meta-analysis shows adjunctive subcutaneous omalizumab may help patients with uncontrolled allergic asthma withdraw from or cut back on corticosteroids. Researchers also…
